NEW YORK, Dec 12 - Diversa said Tuesday it had reached an agreement with Glaxo Wellcome to jointly research novel small molecules in Diversa’s PathwayLibraries.

Under the terms of the non-exclusive deal, Diversa and Glaxo Research and Development, a subsidiary of Glaxo Wellcome, will identify and screen molecules in the database for specific pharmaceutical activity.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.